Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose (90)Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM

類似資料

• Estimates of Radiation-Absorbed Dose to Kidneys in Patients Treated with (90)Y-Ibritumomab Tiuxetan
  著者:: Baechler, Sébastien, 等
  出版事項: (2008)
• Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: The Role of Histology
  著者:: Krishnan, Amrita Y., 等
  出版事項: (2017)
• 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity
  著者:: Mondello, Patrizia, 等
  出版事項: (2015)
• Biodistribution, radiation dosimetry and scouting of (90)Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using (89)Zr-ibritumomab tiuxetan and PET
  著者:: Rizvi, Saiyada N. F., 等
  出版事項: (2012)
• Update on the rational use of (90)Y-ibritumomab tiuxetan in the treatment of follicular lymphoma
  著者:: Lehnert, Martina, 等
  出版事項: (2009)